Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ)

CAPS Rating: 3 out of 5

A specialty pharmaceutical company, which focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

Results 1 - 20 of 48 : 1 2 3 Next »

Recs

0
Member Avatar McRCN (43.10) Submitted: 4/4/2014 5:51:28 PM : Outperform Start Price: $127.13 JAZZ Score: +6.84

buy on pull back.

Recs

0
Member Avatar tdoodler (23.81) Submitted: 3/13/2014 2:23:27 PM : Underperform Start Price: $149.32 JAZZ Score: +9.46

breaks support

Recs

0
Member Avatar DugdaleTiki (39.59) Submitted: 3/3/2014 9:25:10 AM : Outperform Start Price: $147.28 JAZZ Score: -8.47

2014 Sabrient Pick

Recs

0
Member Avatar TerryFool (21.60) Submitted: 2/16/2014 12:58:08 PM : Outperform Start Price: $146.90 JAZZ Score: -8.21

Long term invest, 3YR REV 65% 3YR EPS 100%, TP $200

Recs

0
Member Avatar IRA2014 (44.99) Submitted: 1/21/2014 1:50:25 PM : Outperform Start Price: $149.20 JAZZ Score: -9.99

SBD pick. Went $90-148 in just a couple of months at end of 2013 and was up 150% on the year. I don't like the parabolic rise in the short term. Overall the price still looks reasonable though. earnings growth estimated 24% and PE 23.5 so maybe easy money is made but still "in value". Should outperform market though going forward and by a wide margin if earnings growth holds up . Nice specialty pharma. Expect high volatility and high return over the next year or 2.

Recs

0
Member Avatar mrudolph72 (62.11) Submitted: 1/16/2014 2:06:11 AM : Outperform Start Price: $148.04 JAZZ Score: -9.17

sabrient

Recs

0
Member Avatar reddingrunner (97.48) Submitted: 1/13/2014 4:00:33 PM : Outperform Start Price: $147.00 JAZZ Score: -9.63

sbd

Recs

0
Member Avatar 1picks (85.64) Submitted: 1/13/2014 2:24:18 PM : Outperform Start Price: $147.27 JAZZ Score: -9.73

Sabrient

Recs

0
Member Avatar 2win (< 20) Submitted: 1/9/2014 10:14:15 AM : Outperform Start Price: $138.24 JAZZ Score: -3.04

momentum. JAZZ hits new highs again. This powerful stock has now doubled over the last 6 months. DarvasTrader.

Recs

0
Member Avatar exoblight (< 20) Submitted: 1/4/2014 12:39:20 PM : Outperform Start Price: $127.00 JAZZ Score: +5.62

Gentium acquisition likely to improve bottom line

Recs

0
Member Avatar SqwiiTrader (37.30) Submitted: 12/13/2013 3:53:00 AM : Underperform Start Price: $115.91 JAZZ Score: -13.05

bearish engulfing

Recs

1
Member Avatar grankh (87.50) Submitted: 10/21/2013 1:08:23 AM : Outperform Start Price: $82.98 JAZZ Score: +55.32

Another stock I own personally.

Sales have grown 80% per year on average since 2010. EPS has grown 56% over the past 18 months. The profit margin has fluctuated considerably, so not joy there. The earned-on-equity has fallen in each of the past 2 years, so the wrong trend. Debt has fluctuated also, though is generally down over the past 3 years. The P/E is above its recent average, but lower than it reached in 2010 and 2011, so not unreasonable, (though its earned-on-equity was much higher in those years, so the higher P/E was justified). The PEG ratio is attractive. The company does NOT pay a dividend, so sadness in that area. I mainly bought this stock due to the rapid growth in Sales and EPS, so see if the stock can continue its rapid, upward trajectory.

Even assuming a growth rate at less than half what the company has been growing at over the past few years, I think this stock could gain 16% or more annually for the next 5 years. However, if its earned-on-equity keeps falling, I may revisit this holding to see if I think it can still grow for me at the rate I want it to, especially since it will not pay me a dividend to offset any potential downside due to the lower earnings growth rate. So one to keep an eye on, and hope the growth rates are maintained for a while longer.

Recs

0
Member Avatar talkingdog (88.61) Submitted: 9/26/2013 7:55:22 AM : Outperform Start Price: $88.39 JAZZ Score: +43.96

underpriced?

Recs

0
Member Avatar awallejr (82.72) Submitted: 9/11/2013 8:15:09 PM : Outperform Start Price: $86.01 JAZZ Score: +48.23

Heard about this stock on Pimm Fox's radio show. Kind of wish I heard about it a year ago. Despite its run up it still looks cheap.

Recs

0
Member Avatar chris293 (87.15) Submitted: 9/11/2013 8:12:17 PM : Outperform Start Price: $86.01 JAZZ Score: +48.23

This sounds like the drug company of choice for people with any number of problems.

Recs

0
Member Avatar onecandream (85.43) Submitted: 9/2/2013 11:07:20 AM : Outperform Start Price: $88.95 JAZZ Score: +40.26

IBD 50

Recs

0
Member Avatar s2dbaker (90.96) Submitted: 8/2/2013 6:07:25 AM : Outperform Start Price: $76.50 JAZZ Score: +68.52

Le Jazz Hot!

Recs

0
Member Avatar manirg (41.06) Submitted: 7/30/2013 6:20:40 PM : Outperform Start Price: $75.03 JAZZ Score: +71.14

very undervalued

Recs

0
Member Avatar 1russianguy (61.77) Submitted: 6/20/2013 3:06:54 PM : Outperform Start Price: $65.00 JAZZ Score: +92.79

screen

Recs

0
Member Avatar Pops61 (62.20) Submitted: 3/12/2013 1:41:20 AM : Outperform Start Price: $59.91 JAZZ Score: +107.72

Several drugs for mental illness and non-opiod pain management. Sold under performing subsidiary in June 2012. Fwd P/E 9.26. Upgrade with Target price 87.10.

Results 1 - 20 of 48 : 1 2 3 Next »

Featured Broker Partners


Advertisement